| Assessment Status | Rapid Review complete |
| HTA ID | - |
| Drug | Cabozantinib |
| Brand | Cometriq® |
| Indication | Treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma. For patients in whom Rearranged during Transfection (RET) mutation status is not known or is negative, a possible lower benefit should be taken into account before individual treatment decision. |
| Assessment Process | |
| Rapid review commissioned | 10/07/2014 |
| Rapid review completed | 12/08/2014 |
| Rapid review outcome | Full pharmacoeconomic evaluation recommended at the submitted price. |
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.
